Clinical trial · Interventional
Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women
Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin in Hyperandrogenic Lean PCOS Women
NCT02244567CI-TRIAL-00049792U-C OC IN PCOSunknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
High ucOC may favor insulin release in lean hyperandrogenic women to compensate for impaired insulin sensitivity. Meformin is an insulin sensitizing agent will be given for these women trying to interfere with the pathophysiology of PCOS in these women as followed up by serum UC-OC levels.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| drug | Other | — | UNRESOLVED |
| Metformin 850 mg twice daily for 3 months | Drug | — | UNRESOLVED |
| Serum uc-oc | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Metformin
- description
- Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
- interventionNames
- Drug: Metformin 850 mg twice daily for 3 months
- type
- ACTIVE_COMPARATOR
- label
- Serum under-carboxylated osteocalcin
- description
- Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
- interventionNames
- Procedure: Serum uc-oc
- type
- ACTIVE_COMPARATOR
- label
- Placebo
- description
- Other group of patients with high serum UC-OC will be given a placebo.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Lean women BMI 25 or less * Hyperandrogenic clinically and/or biochemically. * Androgen Excess-Polycystic Ovary Syndrome (AE-PCOS) Society 2006 criteria Exclusion Criteria: * BMI more than 20 * Other causes of hyperandrogenism * Other causes of metabolic disorders or diabetes.
References
Publications (0)
Data not yet available
No reference posted for this study.